(Reuters) – The United States has administered more than 7,300 doses of Novavax Inc’s COVID-19 shot, which health officials hope will convince more people to opt for vaccinations as it is based on a technology that has been in use for decades.

This is the first set of data on the vaccine’s use in the U.S. since its authorization last month.

Novavax vaccine is based on a traditional technology that has been used to combat diseases including hepatitis B and influenza.

(Reporting by Leroy Leo in Bengaluru; Editing by Vinay Dwivedi)

Copyright 2022 Thomson Reuters.

Related Posts

%d bloggers like this: